Penserra Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Penserra Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-765	Closed	-$11K	–	1605
2021 Q3	$11K	Buy	765 +10	+1%	+$160	﹤0.01%	1351
2021 Q2	$15K	Buy	755 +5	+0.7%	+$99	﹤0.01%	1228
2021 Q1	$17K	Sell	750 -15	-2%	-$418	﹤0.01%	989
2020 Q4	$18K	Buy	765 +483	+171%	+$16K	﹤0.01%	863
2020 Q3	$11K	Buy	+282	New	+$13K	﹤0.01%	809

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Penserra Capital Management's ICPT Position: Q4 2021 in Review

Penserra Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 765 shares — an estimated $11K sold.

Penserra Capital Management first reported a position in ICPT in Q3 2020 and held it in 5 quarters. The position peaked at $18K in Q4 2020. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.

Penserra Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 765 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $11K.
Penserra Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2020 and held it in 5 quarters.
Penserra Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $18K in Q4 2020.
147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.